SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer

被引：5

作者：

Westin, Shannon ^{[1
]}

Kurnit, Katherine ^{[2
]}

Fellman, Bryan ^{[1
]}

Bhosale, Priya ^{[1
]}

Hong, David ^{[1
]}

Karp, Daniel ^{[1
]}

Naing, Aung ^{[1
]}

Pant, Shubham ^{[1
]}

Piha-Paul, Sarina ^{[1
]}

Fu, Siqing ^{[1
]}

Rodon, Jordi ^{[1
]}

Yap, Timothy ^{[1
]}

Dumbrava, Ecaterina ^{[1
]}

Sood, Anil ^{[1
]}

Shafer, Aaron ^{[1
]}

Soliman, Pamela ^{[1
]}

Gershenson, David ^{[1
]}

Kabil, Nashwa ^{[3
]}

Coleman, Robert ^{[4
]}

Mills, Gordon ^{[5
]}

Meric-Bernstam, Funda ^{[1
]}

机构：

[1] UT MD Anderson Canc Ctr Houston, Houston, TX USA

[2] Univ Chicago, Coll Med, Chicago, IL USA

[3] AstraZeneca, Gaithersburg, MD USA

[4] US Oncol Res, The Woodlands, TX USA

[5] OHSU, Portland, OR USA

来源：

关键词：

D O I：

10.1016/j.ygyno.2023.06.511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA 9

引用

页码：S33 / S33

页数：1